Sign In
Buy ALLR
$1.19
-0.0300 (-2.46%)
At Close: Jul 24, 2026
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
07:00am, Monday, 29'th Apr 2024
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatm
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
09:10am, Wednesday, 17'th Apr 2024
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatmen
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?
08:18am, Friday, 12'th Apr 2024
Allarity Therapeutics (NASDAQ: ALLR ) stock is heading higher on Friday alongside heavy pre-market trading. Investors will note that this movement comes after the company announced a prospectus suppl
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
09:15am, Thursday, 04'th Apr 2024
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatme
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMP
Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatm
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
07:15am, Friday, 08'th Mar 2024
Boston (March 8, 2024) — Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported fi
Allarity Therapeutics to Present at Biomarkers 2024
06:00am, Wednesday, 28'th Feb 2024
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer tre
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
06:00am, Tuesday, 12'th Dec 2023
Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together
Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?
10:07am, Tuesday, 05'th Dec 2023
Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial s
Boston (December 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together
Allarity Therapeutics to Present at Biomarkers Europe 2023
07:00am, Monday, 02'nd Oct 2023
BOSTON , October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-spe
CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therap
PLOS ONE Publishes Data on Allarity Therapeutics' DRP® Companion Diagnostic for Dovitinib
04:05pm, Wednesday, 30'th Aug 2023
- T he DRP ® -Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment , as compared to u
